The estimated Net Worth of Ken Moseley is at least $1.07 Tysiąc dollars as of 13 July 2017. Ken Moseley owns over 13,823 units of Bellicum Pharmaceuticals Inc stock worth over $1,070 and over the last 10 years Ken sold BLCM stock worth over $0.
Ken has made over 9 trades of the Bellicum Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Ken exercised 13,823 units of BLCM stock worth $35,249 on 13 July 2017.
The largest trade Ken's ever made was exercising 15,000 units of Bellicum Pharmaceuticals Inc stock on 2 June 2016 worth over $38,250. On average, Ken trades about 6,416 units every 53 days since 2015. As of 13 July 2017 Ken still owns at least 14,314 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of Ken Moseley stock trades at the bottom of the page.
Ken's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON, TX, 77030.
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... oraz Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: